Value Line (NASDAQ: VALU) has initiated coverage of Mindray Medical and Ultratech, Inc. in its flagship product, The Value Line Investment Survey . Beginning Monday, August 20 th. Value Line’s analysts are evaluating the performance and business fundamentals of these stocks. The following is based on recent SEC filing information.

Mindray Medical International is a developer, manufacturer, and marketer of a broad range of medical devices across three primary business segments: patient monitoring & life-support products; in-vitro diagnostic products; and medical imaging systems. In 2011, it recorded revenues of more than $880 million, and the stock’s market capitalization exceeds $4.0 billion. The company is headquartered in Nanshan, Shenzhen, China.

Ultratech, Inc. engages in the development, production, and marketing of photolithography and laser thermal processing equipment. It currently offers two different systems for use in the semiconductor fabrication process, and markets its products and services to semiconductor and nanotechnology device manufacturers; 2011 annual sales exceeded $200 million. The company is based in San Jose, California.

For more information about the particular investment merits of Mindray and Ultratech, subscribers can peruse our full-page research reports in The Value Line Investment Survey.

The Value Line Investment Survey, Value Line’s signature publication, is one of the most highly regarded and widely used independent investment research resources. Published weekly, it tracks approximately 1,700 stocks in over 90 industries and ranks those stocks on Timeliness™ and Safety™. It is available both online and in print.